超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究*

doi:10.3969/j.issn.1672-5069.2022.05.014

摘要/Abstract

摘要： 目的探讨采用超声三维斑点追踪技术(3D-STI)评价非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者左心功能的价值。方法 2019年6月～2021年6月我院诊治的60例NAFLD合并T2DM患者(轻度NAFLD 30例,重度30例)和同期30例T2DM患者,检测血清空腹血糖(FPG)、糖化血红蛋白(HbA1c)、谷丙转氨酶(ALT)和谷草转氨酶(AST)水平。采用常规二维超声测量左室舒张末内径(LVDd)、左室收缩末内径(LVDs)和二尖瓣口舒张早期和舒张晚期峰值血流速度比值(E/A比值)。采用实时三维超声测量左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、左室射血分数(LVEF)和左室质量指数(LVMI)。采用3D-STI技术测量左心室整体纵向应变(GLS)、整体周向应变(GCS)、整体径向应变(GRS)和整体面积应变(GAS)。结果重度NAFLD合并T2DM患者血清HbA1c、ALT和AST水平分别为(8.9±2.4)%、(127.2±16.9)U/L和(91.2±11.5)U/L,显著高于轻度NAFLD合并T2DM患者【分别为(7.2±2.9)%、(61.6±10.4)U/L和(60.7±9.6)U/L,P<0.05】或单纯T2DM患者【分别为(7.0±2.5)%、(31.7±5.5)U/L和(33.5±4.8)U/L,P<0.05】;三组LVDd、LVDs、E/A比值、LVEF、LVEDV、LVESV和LVMI比较均无统计学差异(P＞0.05);重度NAFLD合并T2DM患者GLS、GCS、GRS和GAS分别为(14.3±3.9)%、(17.3±3.3)%、(40.6±6.2)%和(24.1±4.6)%,显著低于轻度NAFLD合并T2DM患者【分别为(17.7±2.8)%、(19.4±2.7)%、(44.9±8.7)%和(27.0±4.4)%,P<0.05】或单纯T2DM患者【分别为(18.9±2.4)%、(19.6±3.1)%、(45.5±6.4)%和(28.8±3.6)%,P<0.05】。结论采用3D-STI技术检测可以敏感地反映NAFLD合并T2DM患者左心功能变化,有助于临床早期正确评估其心功能状态。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 左心功能, 超声三维斑点追踪成像, 应变参数

Abstract: Objective The aim of this study was to explore the evaluation of left ventricular functions by three-dimensional speckle tracking imaging (3D-STI) in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods 60 patients with NAFLD and T2DM (mild NAFLD in 30 and severe in 30) and 30 patients with T2DM were admitted in our hospital between June 2019 and June 2021. Serum fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were detected. The left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVDs) and ratio of peak systolic velocity to end-diastolic velocity (E/A) were measured by routine two-dimensional ultrasound. The left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF) and left ventricular mass index (LVMI) were measured by real-time three-dimensional ultrasound. The left ventricular global longitudinal strain (GLS), global circumferential strain (GCS), global radial strain (GRS) and global area strain (GAS) were detected by 3D-STI. Results Serum HbA1c, ALT and AST levels in patients with severe NAFLD and T2DM were (8.9±2.4)%,(127.2±16.9)U/L and (91.2±11.5)U/L, significantly higher than[(7.2±2.9)%, (61.6±10.4)U/L and (60.7±9.6)U/L, respectively, P<0.05] in patients with mild NAFLD and T2DM or [(7.0±2.5)%, (31.7±5.5)U/L and (33.5±4.8)U/L, respectively, P<0.05] in patients with T2DM; there were no significant differences in LVDd, LVDs, ratio of E/A, LVEF, LVEDV, LVESV and LVMI among the three groups (P＞0.05); the GLS, GCS, GRS and GAS in patients with severe NAFLD and T2DM were (14.3±3.9)%, (17.3±3.3)%, (40.6±6.2)% and (24.1±4.6)%, significantly lower than [(17.7±2.8)%, (19.4±2.7)%, (44.9±8.7)% and (27.0±4.4)%, respectively, P<0.05] in patients with mild NAFLD and T2DM or [(18.9±2.4)%, (19.6±3.1)%, (45.5±6.4)% and (28.8±3.6)%, respectively, P<0.05] in patients with T2DM. Conclusion The 3D-STI detection could sensitively reflect changes of left ventricular functions in patients with NAFLD and T2DM, which is beneficial to correctly evaluate impairment of cardiac functions in this setting.

Key words: Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Left ventricular functions, Three-dimensional speckle tracking imaging, Strain parameter

奚佳颖, 汤佳美, 刘玲玉, 王韦. 超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 661-664.

Xi Jiaying, Tang Jiamei, Liu Lingyu, et al.. Evaluation of left ventricular functions by three-dimensional speckle tracking imaging in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2022, 25(5): 661-664.

参考文献

[1]Schonfels W, Beckmann JH, Ahrens M, et al. Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis, 2018, 14(10):1607-1616.
[2]梁小丽,邝继孙,刘秋莉,等.非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究.实用肝脏病杂志,2021,24(1):51-54.
[3]Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): diagnosis, pitfalls, and staging. Ann Diagn Pathol, 2018, 37(1):83-90.
[4]Eslam M , Valenti L , Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol, 2018, 28(2):268-279.
[5]Khan RS, Bril F, Cusi K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology, 2019, 70(2):711-724.
[6]Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017, 49(2):197-211.
[7]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版).实用肝脏病杂志,2018,21(2):177-186.
[8]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版).中华糖尿病杂志,2018,10(1):4-67.
[9]Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020, 69(9):1691-1705.
[10] Cassidy S, Hallsworth K, Thoma C,et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol, 2015, 14(1):23.
[11] 孙娟娟, 王志斌, 何香芹,等. 三维斑点追踪成像评价血压控制程度对高血压患者早期收缩功能的影响. 中华高血压杂志, 2019, 27(3):283-286.
[12] Tanase DM, Gosav EM, Costea CF,et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res, 2020, 2020(1):3920196.
[13] Lee H, Kim G, Choi YJ,et al. Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus. Diabetes Metab J, 2020, 44(2):267-276.
[14] Chang W, Wang Y, Sun L,et al. Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography. Echocardiography, 2019, 36(7):1290-1297.
[15] Mantovani A, Pernigo M, Bergamini C,et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One, 2015, 10(8):e0135329.
[16] 南月敏,付娜,李文聪,等.2017美国非酒精性脂肪性肝病诊断与管理指南解读.中华肝脏病杂志,2017,25(9):687-694.
[17] Yu C, Wang L, Xue H,et al. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. Clin Res Hepatol Gastroenterol, 2019, 43(1):58-66.
[18] Shi C, Wang LJ, Hu DF,et al. Prevalence, clinical characteristics and outcome in patients with chronic heart failure and diabetes. Chin Med J (Engl), 2010, 123(6):646-650.
[19] Trovato FM, Martines GF, Catalano D,et al. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol, 2016, 221(1):275-279.
[20] 余珊珊,孙露,韩东刚,等.超声三维斑点追踪技术检查肝硬化患者左心室收缩功能初步研究.实用肝脏病杂志,2018,21(2):245-248.
[21] VanWagner LB, Wilcox JE, Colangelo LA,et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology, 2015, 62(3):773-783.
[22] Karabay CY, Kocabay G, Kalayci A,et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur J Gastroenterol Hepatol, 2014, 26(3):325-331.

超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*

Evaluation of left ventricular functions by three-dimensional speckle tracking imaging in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[2]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[3]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[4]	王慧, 汤展, 常文娟, 芦超. 非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 669-672.
[5]	陈梦绮, 范建高. 美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介^*[J]. 实用肝脏病杂志, 2022, 25(5): 0-S16.
[6]	章思懿, 施军平. 重视内分泌系统疾病造成的肝损伤[J]. 实用肝脏病杂志, 2022, 25(4): 457-459.
[7]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[8]	汪晓燕, 钟雪玉, 吴春燕. 沙格列汀干预非酒精性脂肪性肝病合并2型糖尿病大鼠肝组织AMPK/mTOR-TFEB自噬信号通路蛋白表达变化^*[J]. 实用肝脏病杂志, 2022, 25(4): 476-479.
[9]	张文彦, 刘芳, 刘梦露, 陈德喜, 张晶, 时红波, 于海滨. 非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 521-525.
[10]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[11]	年福临, 鲁晓岚. 糖尿病与非酒精性脂肪性肝病^*[J]. 实用肝脏病杂志, 2022, 25(3): 314-317.
[12]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[13]	蔡冬梅, 吴文娟, 姜亦伦, 居敏昊. CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 383-386.
[14]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[15]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.